Biochemical and molecular detection of genetic instability of liver cancer

Elmekawy,Shimaa F.; Mahmoud,Ashraf Z.; Abdelhady,Elsayed K.; Aboelenin,Ahmed M.

doi:10.3892/wasj.2024.296

Biochemical and molecular detection of genetic instability of liver cancer

Authors:
- Shimaa F. Elmekawy
- Ashraf Z. Mahmoud
- Elsayed K. Abdelhady
- Ahmed M. Aboelenin
View Affiliations

Affiliations: Department of Zoology, Faculty of Science, Mansoura University, Mansoura 35516, Egypt, Department of Urology and Nephrology, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt, Department of Gastroenterology Surgery, Faculty of medicine, Mansoura University, Mansoura 35516, Egypt
Published online on: November 19, 2024 https://doi.org/10.3892/wasj.2024.296
Article Number: 8
Copyright : © Elmekawy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver cancer has become the third most common cause of mortality worldwide. Random amplified polymorphic DNA analysis (RAPD) is used in cancer research. This analysis was used in the present study in an aim to examine the genetic instability of liver cancer. For this purpose, a total of 20 patients with liver cancer between the ages of 45 and 80 years of both sexes were randomly selected in the present study. Blood samples were collected for hematological and biochemical analyses. Radiological, etiological and histopathological data were analyzed and liver tissue biopsies from the tumor and safe area were obtained for RAPD‑PCR testing. The results revealed that 50% of the patients had fatty liver cirrhosis, 40% had hepatitis C virus infection and 10% had hepatitis B virus infection. Of note, 85% of the patients had hepatocellular carcinoma, 15% had mixed‑type carcinoma, 10% had fibrolamellar carcinoma and 5% had hepatic adenoma. In addition, 80% of the patients had grade II disease, 15% had grade III disease and 5% had grade I disease, while 40% of patients had stage I disease, 30% of patients had stage III disease, 20% of patients had stage II disease and 10% of patients had stage IV disease. The analysis of radiological data revealed that 50% of the patients had fatty liver cirrhosis, 85% had large tumors and 15% had smaller tumors. Of note, 10% of the studied patients had lymph node metastasis, and 90% of them did not have metastasis. All the values for the hematological parameters were decreased; however, the white blood cell count and the international normalized ratio (INR) were significantly increased. The serum levels of bilirubin, creatinine, potassium, alpha‑fetoprotein, alanine transaminase and aspartate aminotransferase were significantly increased, whereas those of albumin and sodium were significantly decreased. The RAPD‑PCR analysis of both normal and tumor tissue biopsies revealed the marked appearance of a tumor marker band1, 150 bp in 26% of the normal tissue samples, and in 57% of the tumor samples when primer A‑01 was used. Furthermore, tumor marker band 1,850 bp appeared in 24% of the normal tissues and in 82% of the tumor tissues when A‑03 primer was used. On the whole, the present study demonstrates the instability of liver cancer based on biochemical and molecular detection aspects.

View Figures

View References

1	Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS and Wolkoff AW: The Liver: Biology and Pathobiology. 6^th edition. Wiley-Blackwell, Hoboken, NJ, 2020.
2	Pan F, Huang Q and Li X: Classification of liver tumors with CEUS based on 3D-CNN. In: 2019 IEEE 4th international conference on advanced robotics and mechatronics (ICARM). IEEE 845-849, 2019.
3	Wang ZG, He ZY, Chen YY, Gao H and Du XL: Incidence and survival outcomes of secondary liver cancer: A surveillance epidemiology and end results database analysis. Transl Cancer Res. 10:1273–1283. 2021.PubMed/NCBI View Article : Google Scholar
4	Shannon AH, Ruff SM and Pawlik TM: Expert insights on current treatments for hepatocellular carcinoma. Clinical and molecular approaches and bottlenecks to progress. J Hepatocell Carcinoma. 9:1247–1261. 2022.PubMed/NCBI View Article : Google Scholar
5	Rashed WM, Kandeil MAM, Mahmoud MO and Ezzat S: Hepatocellular carcinoma (HCC) in Egypt. A comprehensive overview. J Egypt Natl Can Inst. 32(5)2022.PubMed/NCBI View Article : Google Scholar
6	Piñero FF, Dirchwolf M and Pessôa MG: Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells. 9(1370)2020.PubMed/NCBI View Article : Google Scholar
7	Jahnke G, Smidla J and Poczai P: MolMarker: A simple tool for DNA fingerprinting studies and polymorphic information content calculation. Diversity. 14(497)2022.
8	Al-Samarai FR and Al-Kazaz AA: Molecular markers: An introduction and applications. Eur J Mol Biotechnol. 9:118–130. 2015.
9	Senthil N and Gurusubramanian G: Random amplified polymorphic DNA (RAPD) markers and its applications. Sci Vis. 11:116–124. 2011.
10	Allami ZZG and Dragh MA: Identification of some breast cancer related genes by RAPD technique in Maysan Province Iraq. Revis Bionatura. 7:20–28. 2022.
11	El-Far M, Abol-Enein H, Zakaria A and El-Gedamy M: Detection of genomic instability in renal cancer by random amplified polymorphic DNA analysis from urine samples as a non-invasive method: Potential use in diagnosis. Cancer Sci Res. 1(7)2013.
12	Xian ZH, Cong WM, Zhang SH and Wu MC: Genetic alterations of hepatocellular carcinoma by random amplified polymorphic DNA analysis and cloning sequencing of tumor differential DNA fragment. World J Gastroenterol. 11:4102–4107. 2005.PubMed/NCBI View Article : Google Scholar
13	El-Far M, Abol-Enein H, Zakaria A and El-Gedamy M: Application of random amplified polymorphic DNA-PCR technique in early diagnosis of bladder cancer using urine samples. Curr Top Bio Res. 15:23–34. 2013.
14	Ibrahim MA, Saleh NA, Archoukieh E, Al-Obaide HW, Al-Obaidi MM and Said HM: Detection of novel genomic polymorphism in acute lymphoblastic leukemia by random amplified polymorphic DNA analysis. Int J Cancer Res. 6:19–26. 2010.
15	Zakaria A and Mahmoud AZ: Molecular characterization of TP53 gene mutations in human bladder cancer. Pharm Biotechnol. Curr Res. 2:1–7. 2017.
16	Armitage P, Berry G and Matthews JNS: Statistical Methods in Medical Research. 4th edition. Wiley-Blackwell, Hoboken, NJ, 2002.
17	Bale R, Schullian P, Eberle G, Putzer D, Zoller H, Schneeberger S, Manzl C, Moser P and Oberhuber G: Stereotactic radiofrequency ablation of hepatocellular carcinoma: A histopathological study in explanted livers. Hepatology. 70:840–850. 2019.PubMed/NCBI View Article : Google Scholar
18	Suresh D, Srinivas AN and Kumar DP: Etiology of hepatocellular carcinoma: Special focus on fatty liver disease. Front Oncol. 10(601710)2020.PubMed/NCBI View Article : Google Scholar
19	Loy LM, Low HM, Choi JY, Rhee H, Wong CF and Tan CH: Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification: An imaging-focused review. AJR Am J Roentgenol. 219:212–223. 2022.PubMed/NCBI View Article : Google Scholar
20	Martins-Filho SN, Paiva C, Azevedo RS and Alves VAF: Histological grading of hepatocellular carcinoma-A systematic review of literature. Front Med. 4(193)2017.PubMed/NCBI View Article : Google Scholar
21	Szklaruk J, Silverman PM and Charnsangavej C: Imaging in the diagnosis, staging, treatment, and surveillance of hepatocellular carcinoma. AJR Am J Roentgenol. 180:441–454. 2003.PubMed/NCBI View Article : Google Scholar
22	Elgamal S, Ghafar AA, Ghoneem E, Elshaer M, Alrefai H and Elemshaty W: Characterization of patients with hepatocellular carcinoma on the way for early detection: One center experience. Egypt J Int Med. 30:231–238. 2018.
23	Omar M, Elazab T, Abdelrahman A and Mohamed E: Clinical significance of serum midkine level as a biomarker in diagnosis of hepatocellular carcinoma. Benha Med J (Internal Med Hepatol) Special Issue. 37:37–46. 2020.
24	Fang Y, Sun X, Zhang L, Xu Y and Zhu W: Hemoglobin/red blood cell distribution width ratio in peripheral blood is positively associated with prognosis of patients with primary hepatocellular carcinoma. Med Sci Monit. 28:e937146–1. 2022.PubMed/NCBI View Article : Google Scholar
25	Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford A, et al: Guidelines on the management of abnormal liver blood tests. Gut. 67:6–19. 2018.PubMed/NCBI View Article : Google Scholar
26	Mohamed BF, Serag WM, Abdelal RM and Elsergany HF: S100A14 protein as diagnostic and prognostic marker in hepatocellular carcinoma. Egypt Liver J. 9:1–6. 2019.
27	Carr BI and Guerra V: Serum albumin levels in relation to tumor parameters in hepatocellular carcinoma patients. Int J Biol Markers. 32:e391–e396. 2017.PubMed/NCBI View Article : Google Scholar
28	Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S and Osaki Y: Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer. 6:482–489. 2015.PubMed/NCBI View Article : Google Scholar
29	Guerra Ruiz AR, Crespo J, LópezMartínez RM, Iruzubieta P, Casals Mercadal G, Lalana Garcés M and Morales Ruiz M: Measurement and clinical usefulness of bilirubin in liver disease. Adv Lab Med. 2:352–361. 2021.PubMed/NCBI View Article : Google Scholar
30	Watanabe M, Yokomori H, Takahashi Y, Okada T, Shibuya A and Koizumi W: Assessing the characteristics and feasibility of preventing early mortality in patients with hepatocellular carcinoma. The Turkish J Gastroenterol. 30:541–548. 2019.PubMed/NCBI View Article : Google Scholar
31	Singh Y, Nagar D, Singh M and Maroof M: Study of electrolyte disturbance in chronic liver disease patients attending a hospital in Kumaon region. J Family Med Primary Care. 11:4479–4482. 2022.PubMed/NCBI View Article : Google Scholar
32	Zhang J, Chen G, Zhang P, Zhang J, Li X, Gan DN and Ye YA: The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One. 15(e0228857)2020.PubMed/NCBI View Article : Google Scholar
33	Chen W, Wang W, Zhou L, Zhou J, He L, Li J, Xu X, Wang J and Wang L: Elevated AST/ALT ratio is associated with all-cause mortality and cancer incident. J Clin Lab Anal. 36(e24356)2022.PubMed/NCBI View Article : Google Scholar
34	Zhang H, Gao C, Fang L and Yao SK: Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus. World J Gastroenterol. 19:2395–2403. 2013.PubMed/NCBI View Article : Google Scholar
35	Zhang SH, Cong WM, Xian ZH, Dong H and Wu MC: Genomic instability in hepatocellular carcinoma revealed by using the random amplified polymorphic DNA method. J Cancer Res Clin Oncol. 130:757–761. 2004.PubMed/NCBI View Article : Google Scholar
36	Chariyalertsak S, Khuhaprema T, Bhudisawasdi V, Sripa B, Wongkham S and Petmitr S: Novel DNA amplification on chromosomes 2p25.3 and 7q11.23 in cholangiocarcinoma identified by arbitrarily primed polymerase chain reaction. J Cancer Res Clin Oncol. 131:821–828. 2005.PubMed/NCBI View Article : Google Scholar